Table 5.
Polymeric Nanocarriers Obtained and Characterized in vivo for Delivery of Drugs for Neurological Disorders
| Nanocarriers | Transporting Agent | Route of Administration | Animal Model | Application | Targeting |
|---|---|---|---|---|---|
| PCL nanocarriers159 | p,p’-methoxyl-diphenyl diselenide | i.g. | Swiss mice with the chronic pain-like behavior induced by the partial sciatic nerve ligation surgery | Neuropathic pain treatment | – |
| Polysorbate 80; chitosan PEGylated nanocarriers160 | Clozapine | i.p. or i.v. | Healthy or amphetamine-induced pseudo-psychosis Wistar rats | Schizophrenia treatment | – |
| NFL-TBS.40–63 polypeptide nanocarriers161 | – | Injection in the brain right lateral ventricle or the spinal cord | Healthy Sprague- Dawley rats | Neuronal disorders treatment | Neural stem cells |
| PLGA nanocarriers containing triphenylphosphonium162 | Quercetin | Oral gavage | Cerebral ischemia-induced in Wistar rats | Neuro-protective role in cerebral ischemia-reperfusion | Mitochondria |
| Lecithin/chitosan nanocarriers163 | Simvastatin | Intranasally | Healthy Wistar rats | Neuro-degenerative diseases treatment | – |
Abbreviations: i.g., intragastric; i.p., intraperitoneal; i.v., intravenous; PCL, poly-e-caprolactone; PEG, poly(ethylene glycol); PLGA, poly(lactide-co-glycolide).